Acumen Pharmaceuticals (ABOS) Amortizatization of Intangibles (2021 - 2026)
Acumen Pharmaceuticals (ABOS) reported Amortizatization of Intangibles of -$25000.0 for Q1 2026, down 104.25% on a YoY basis from $588000.0 in Q1 2025, and up 77.27% sequentially from -$110000.0 in Q4 2025.
Acumen Pharmaceuticals (ABOS) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 6 years of Amortizatization of Intangibles data on file, last reported at -$25000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 104.25% year-over-year to -$25000.0; the trailing twelve-month figure through Mar 2026 stood at $196000.0 (down 94.9% YoY), and the FY2025 full-year result was $809000.0, down 83.87% from the prior year.
- Amortizatization of Intangibles advanced to -$25000.0 in Q1 2026, from -$110000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.8 million in Q4 2023 to a low of -$216000.0 in Q1 2022.
- A 5-year average of $496058.8 and a median of $300000.0 in 2023 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles jumped 1919.32% in 2023 and slumped 126.44% in 2025, its largest moves.
- Tracing ABOS's Amortizatization of Intangibles over 5 years: stood at $88000.0 in 2022, then jumped by 1919.32% to $1.8 million in 2023, then plunged by 76.59% to $416000.0 in 2024, then slumped by 126.44% to -$110000.0 in 2025, then soared by 77.27% to -$25000.0 in 2026.
- Business Quant data shows ABOS's Amortizatization of Intangibles at -$25000.0 in Q1 2026, -$110000.0 in Q4 2025, and $275000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Acumen Pharmaceuticals | 140.98 Mn | 140.98 Mn | - | -25,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25,000.00 |
| Mar 31, 2026 | -25,000.00 |
| Dec 31, 2025 | -110,000.00 |
| Dec 31, 2025 | -110,000.00 |
| Sep 30, 2025 | 275,000.00 |
| Sep 30, 2025 | 275,000.00 |
| Jun 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 56,000.00 |
| Mar 31, 2025 | 588,000.00 |
| Mar 31, 2025 | 588,000.00 |
| Dec 31, 2024 | 416,000.00 |
| Dec 31, 2024 | 416,000.00 |
| Sep 30, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Dec 31, 2023 | 1.78 Mn |